Log In
Print
BCIQ
Print
Print this Print this
 

Curosurf, poractant alfa

  Manage Alerts
Collapse Summary General Information
Company Chiesi Farmaceutici S.p.A.
DescriptionPoractant alpha
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic
Latest Stage of DevelopmentMarketed
Standard IndicationRespiratory distress syndrome (RDS)
Indication DetailsTreat respiratory distress syndrome (RDS) in premature infants
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today